Ahmedabad (Gujarat) [India], February 13: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies, has reported a standalone net profit of Rs. 20.77 crore for the Q3 FY25 ended December 2024 as against a net profit of Rs. 28.04 crore in the corresponding period last year. Revenue from operations for the Q3 FY25 was reported […]
Continue Reading
Ahmedabad (Gujarat) [India] November 14: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported standalone net profit of Rs. 50.03 crore for the half year ended 30th September 2024, growth of 7.55% Y-O-Y as compared to the net profit of Rs. 46.52 crore in H1 FY24. Income from operation for the H1 FY25 […]
Continue Reading
Ahmedabad (Gujarat) [India], August 10: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has continued to report excellent operational and financial performance for Q1 FY 2024-25 ended 30th June 2024. Company has reported a standalone net profit of Rs. 23.67 crore for the Q1 FY 2024-25 as compared to the net profit of Rs. […]
Continue Reading
Total Income for Q1FY24 grew 10.27% Y-o-Y to Rs. 143.31 crore. Company has set a target of achieving Rs. 750 crore revenue by FY26 Financial Highlights (Standalone) Q1 FY24 Q1 FY23 Y-O-Y FY23 FY22 Y-O-Y Total Income 143.31 129.97 10.27% 532.79 482.08 10.52% EBITDA 28.41 23.41 21.36% 111.65 105.47 5.86% Profit before Tax 25.45 […]
Continue Reading
Mr. Mahendra Patel, MD, Lincoln Pharmaceuticals Ltd Company in the elite club of just 16 companies out of 4,200 plus companies listed on the Indian Stock Exchange to do so Ahmedabad (Gujarat) [India], July 31: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies, has achieved the milestone of reporting a profit growth every single […]
Continue Reading
Mr . Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd Highlights:- · Total Income from operation in Q2 FY23 at ₹ 146.30 crore, up 12.5% from ₹ 130.00 crore in Q1 FY23; · During the year, company got an approval from WHO-GMP for Tablet Capsule, dry-powder Suspension products at Cephalosporin plant. · Approved dividend of ₹ […]
Continue Reading